Related Experiment Video
Updated: Jun 20, 2026
09:38
Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
Published on: April 14, 2016
[Pharmacodynamics of pain perception and polymorphism]
1Department of Anesthesiology, Saitama Medical University Hospital, Saitama 350-0495.
Masui. the Japanese Journal of Anesthesiology
|September 22, 2009
Summary
Enzymatic regulation evolved from mass action to genetic control, influencing drug response and pain mechanisms. Genetic polymorphism explains diverse patient sensitivities to drugs like opioids and neuropathic pain.
Area of Science:
- Biochemistry
- Pharmacology
- Genetics
Context:
- Enzyme regulation has evolved from basic mass action to complex genetic and allosteric controls.
- Cellular energy charge also acts as a regulatory mechanism for metabolic pathways like glycolysis.
- Pharmacodynamics traditionally uses concentration-effect curves, but genetic factors introduce complexity.
Purpose:
- To explore the historical and molecular mechanisms of enzyme regulation.
- To connect enzyme regulation to cellular economy and metabolic pathways.
- To investigate the genetic basis of diverse drug responses and pain mechanisms.
Summary:
- Biotransformation regulation progressed from mass action to allosteric control and enzyme induction via genetic analysis.
- Energy charge emerged as a regulatory mechanism for the glycolytic pathway.
- Genetic factors, including silent genes and polymorphism, explain patient variability in drug sensitivity (e.g., opioids) and pain conditions (e.g., neuropathic pain).
Impact:
- Understanding these regulatory layers provides insight into drug efficacy and patient variability.
- Genetic analysis, particularly polymorphism, is crucial for personalized medicine and understanding complex diseases.
- This knowledge aids in developing targeted therapies for pain and optimizing drug treatments.
Related Concept Videos
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:22Opioid Receptors: Overview
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
01:44Nociception
Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain. Thus, pain helps the...